Links de passagem do livro para Abbreviations and acronyms
aDSM
active TB drug-safety monitoring and management
AFB
acid-fast bacilli
AIDS
acquired immunodeficiency syndrome
aIPD
adult individual patient data
aOR
adjusted odds ratio
aRR
adjusted risk ratio
ART
antiretroviral therapy
BMI
body mass index
BPaL
bedaquiline, pretomanid and linezolid
BPaLC
bedaquiline, pretomanid, linezolid and clofazimine
BPaLM
bedaquiline, pretomanid, linezolid and moxifloxacin
CI
confidence interval
CL
confidence limits
CNS
central nervous system
DELIBERATE
DELamanId Bedaquiline for ResistAnt TubErculosis (trial)
DR-TB
drug-resistant tuberculosis
DST
drug susceptibility testing
ECG
electrocardiogram
EDRWeb
Electronic Drug-Resistant Tuberculosis Register (South Africa)
FDC
fixed-dose combination (medicines)
GDF
Global Drug Facility
GDG
Guideline Development Group
GRADE
Grading of Recommendations Assessment, Development and Evaluation
HIV
human immunodeficiency virus
HR
isoniazid–rifampicin
HREZ
isoniazid–rifampicin–ethambutol–pyrazinamide
(H)REZ
(isoniazid optional)–rifampicin–ethambutol–pyrazinamide
Hr-TB
rifampicin-susceptible, isoniazid-resistant tuberculosis
IPD
individual patient data (or dataset)
IQR
interquartile range
LPA
line probe assay
M. tuberculosis
Mycobacterium tuberculosis
MDR-TB
multidrug-resistant tuberculosis
MDR/RR-TB
multidrug- or rifampicin-resistant tuberculosis
MIC
minimum inhibitory concentration
MSF
Médecins Sans Frontières
NExT
Newer and Emerging Treatment for MDR/RR-TB (trial)
NTP
national TB programme
PICO
population, intervention, comparator and outcomes
People with HIV
people living with HIV
pre-XDR-TB
pre-extensively drug-resistant tuberculosis
QTcF
corrected QT interval by Fredericia
RCT
randomized controlled trial
RD
risk difference
REZ
rifampicin–ethambutol–pyrazinamide
RR
risk ratio
RR-TB
rifampicin-resistant tuberculosis
SAT
self-administered therapy (also meaning unsupervised treatment)
SRL
TB Supranational Reference Laboratory
STREAM
Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients with MDR-TB (trial)
TB
tuberculosis
US CDC
United States Centers for Disease Control and Prevention
USA
United States of America
WHO
World Health Organization
WHO/GTB
Global Tuberculosis Programme of the World Health Organization
XDR-TB
extensively drug-resistant tuberculosis
TB medicines
B or Bdq
bedaquiline
C or Cfz
clofazimine
Cs
cycloserine
Dlm
delamanid
E
ethambutol
Eto
ethionamide
FQ
fluoroquinolones
H
isoniazid
Hh
isoniazid high dose
Ipm-Cln
imipenem–cilastatin
L or Lzd
linezolid
Lfx
levofloxacin
M or Mfx
moxifloxacin
Mpm
meropenem
P or Rpt
rifapentine
Pa
pretomanid
PAS
P-aminosalicylic acid
Pto
prothionamide
R
rifampicin
Z
pyrazinamide